iRhythm at 2025 Truist Securities MedTech Conference: Strategic Growth Plans

iRhythm Technologies (IRTC) presented at the Truist Securities MedTech Conference, highlighting its over 20% growth in Q1 2025 driven by its leadership in long-term continuous monitoring (LTCM) where it holds over 70% market share. The company is expanding into primary care, targeting 15.5 million symptomatic patients, and plans to submit its Zio MCT device to the FDA by Q3 2025, while also focusing on completing FDA remediation efforts, which are over 80% complete; management indicated that clinical studies like Camelot and Avalon are enhancing market share and payer access, with one market access win allowing patients to bypass short-term Holter monitoring.

Analysis

iRhythm Technologies (IRTC) demonstrated robust Q1 2025 performance with growth exceeding 20%, building on acceleration seen throughout 2024. This momentum is largely attributed to its dominant position in the long-term continuous monitoring (LTCM) market, where it commands over 70% share, and a 30% share of its overall core market of 6.5 million tests. The company is strategically expanding its reach into the primary care segment, which already accounted for a third of prescriptions in the most recent quarter (up from 21% for full-year 2023) and targets an estimated 15.5 million symptomatic patients annually. A key upcoming catalyst is the planned FDA submission of its next-generation Zio MCT device by Q3 2025, which features an extended 21-day wear time and aims to capture greater share in the mobile cardiac telemetry (MCT) market, where iRhythm currently holds a low-to-mid teens percentage. Concurrently, iRhythm is diligently addressing FDA 483 observations, with over 80% of remediation activities completed and full resolution of the initial plan anticipated by Q3, alongside further voluntary quality management system enhancements extending through year-end. Clinical studies such as Camelot and Avalon are proving effective in differentiating Zio technology, leading to market share gains and improved payer access, exemplified by a major payer removing a pre-authorization step for LTCM for 10 million covered lives. The company also retained 85% of business acquired during a recent competitor disruption, underscoring its strong market position and product appeal.

Key Decisions for Investors

• Investors should acknowledge iRhythm's strong growth trajectory and market leadership in LTCM, while closely monitoring the successful completion of FDA remediation efforts expected in Q3 and any subsequent FDA inspections, as this remains a critical de-risking event.
• The planned Q3 2025 FDA submission for Zio MCT presents a significant growth opportunity; therefore, tracking the submission timeline and subsequent regulatory feedback will be crucial for assessing future market share expansion in the MCT segment.
• Consider the ongoing penetration into the primary care market and strategic partnerships with value-based care entities as key drivers for sustained volume growth and market expansion beyond symptomatic patients, assessing the pace of adoption and its impact on revenue.